Neurology
| Chapter 1 Multiple Sclerosis Basics Last Reviewed: May 24, 2010 |
||
| Chapter 2 MRI and New Imaging Technologies in Multiple Sclerosis Last Reviewed: May 24, 2010 |
||
| Chapter 3 Currently Available Treatments for Multiple Sclerosis Last Reviewed: May 24, 2010 |
||
| Chapter 4 Small-Molecule Treatments In Development for Multiple Sclerosis Release date: May 25, 2010 |
||
| Chapter 5 Monoclonal Antibodies in Development for Multiple Sclerosis Release date: May 25, 2010 |
||
| Chapter 6 Managing Symptoms in Multiple Sclerosis Release date: July 14, 2010 |
||
|
||
|
| Table of Contents |
|
Chapter 6 - Managing Symptoms in Multiple Sclerosis |
|
NEW CHAPTER Many patients with multiple sclerosis (MS) live with symptoms that can increase disability and reduce quality of life. Clinicians should review and address these symptoms at each visit to ensure a comprehensive approach to the management of MS. This chapter of Living Medical Textbook Neurology: Multiple Sclerosis 2010 Edition reviews the management of a number of common symptoms: spasticity, gait impairment, fatigue, cognitive impairment, depression, and bladder dysfunction.  top |
| |
|
Chapter 5 - Monoclonal Antibodies in Development for Multiple Sclerosis |
|
NEW CHAPTER WITH UPDATES FROM AAN 2010 Monoclonal antibodies (mAbs) targeting specific cell-surface molecules on immune system cells have proven to be a successful strategy for development of novel treatments for multiple sclerosis (MS). mAbs currently in late-stage development offer the potential for increased efficacy and more convenient dosing schedules, and are helping to expand knowledge of MS pathogenesis. In this chapter of the Living Medical Textbook: Multiple Sclerosis Edition, Dr. Clyde Markowitz describes the mechanism of action, efficacy, and safety profile of mAbs in late-stage clinical trials. This chapter now contains updates on these mAbs from recently published articles and the 2010 annual meeting of the American Academy of Neurology. top |
| |
|
Chapter 4 - Small-Molecule Treatments In Development for Multiple Sclerosis |
|
NEW CHAPTER WITH UPDATES FROM AAN 2010 Improved understanding of MS pathophysiology has led to identification of new targets and development of numerous new therapies. Small molecules offer the potential for the imminent introduction of oral therapies into the armamentarium for MS. In this chapter of Living Medical Textbook: Multiple Sclerosis Edition, Dr. Clyde Markowitz reports on a number of emerging MS therapies in development, focusing on study data, mechanism of action, and side effects of each agent. This chapter now contains updates from the recently published phase III clinical trials of two oral agents as well as presentations made at the 2010 annual meeting of the American Academy of Neurology. top |
| |
|
Chapter 3 - Currently Available Treatments for Multiple Sclerosis |
|
CHAPTER UPDATED Dr. Cohen provides an up-to-date account of available therapies for treating acute relapse and use of disease-modifying therapies to prevent relapse and disease progression. He describes the mechanism of action, efficacy, safety, dosing, and administration of each therapy. Comparative data are considered, along with individualized patient factors that should influence choice of initial therapy. Dr. Cohen also discusses candidacy for treatment and timing of therapy, including the latest data on the merits of initiating therapy in patients with clinically isolated syndrome. Hyperlinks throughout the chapter extend learning by providing greater depth on selected key topics. top |
| |
|
Chapter 2 - MRI and New Imaging Technologies in Multiple Sclerosis |
|
NEW CHAPTER Magnetic resonance imaging (MRI) is the primary imaging technology used in the diagnosis and monitoring of multiple sclerosis (MS). This second chapter of the MS Living Medical Textbook reviews how to interpret conventional MRI and discusses current thinking on the use of serial MRI to monitor MS patients and how the findings should influence management. The recent update to the Consortium of Multiple Sclerosis Centers standardized protocol, which facilitates comparison of serial MRIs, is discussed. This chapter also covers emerging imaging technologies that may eventually complement conventional MRI, including atrophy measures, magnetic resonance spectroscopy, magnetic transfer ratios, diffusion tensor imaging, and susceptibility weighted imaging. top |
| |
|
Chapter 1 - Multiple Sclerosis Basics |
|
CHAPTER UPDATED Multiple Sclerosis Basics is the first chapter of a Living Medical Textbook on the comprehensive management of multiple sclerosis (MS). In this chapter, Scott Zamvil, MD, provides a broad overview of current thinking and controversies regarding the etiology, pathogenesis, classification, and diagnosis of MS. Hyperlinks throughout the chapter lead the reader to more detailed and specific information on these topics from a variety of sources on the Internet in a multitude of formats. The discussion of immunopathogenesis and disease course of MS in Chapter 1 sets the stage for the next two chapters of this book, which will focus on current and emerging MS therapies, including their mechanisms of action, efficacy, and safety. top |
| |
|
| CME INFORMATION |
ACTIVITY GOAL |
| The goal of this CME/CE activity is to examine the pathophysiology, etiologic factors, classification, diagnostic criteria, and current and emerging strategies for treating and managing patients with multiple sclerosis. |
TARGET AUDIENCE |
| This CME/CE activity is designed for neurologists, internal medicine specialists, family practice/primary care physicians, nurse specialists/nurse practitioners, physician assistants, and other health professionals who interact with and are involved in the management and treatment of patients with multiple sclerosis. |
LEARNING OBJECTIVES |
|
| top1945 |
|
|||
|
|||
|
These independent CME/CE activities are supported by an educational grant from Teva Neuroscience.
|
|||
| EDITORIAL BOARD | |||
| EDITOR-IN-CHIEF Bruce A. Cohen, MD |
|||
|
|||
| CONTRIBUTING EDITOR Clyde E. Markowitz, MD |
|||
|
|||
| CONTRIBUTING EDITOR Daniel Pelletier, MD |
|||
|
|||
| CONTRIBUTING EDITOR Scott S. Zamvil, MD, PhD |
|||
|
|||
